Thyroid Eye Disease
Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease
Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.
Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease
High-risk adults with active thyroid eye disease, such as smokers, women and older adults, experienced a reduction in outward bulging of the eye at 24 weeks that was similar to adults at lower risk for the disease, according to findings accepted for presentation at the Endocrine Society Annual Meeting.
Immunovant’s thyroid eye disease treatment shows positive phase 2a results
Top stories in endocrinology: Blood test estimates final menstrual period, FDA OKs novel thyroid eye disease treatment
Researchers said a blood test can show when a woman may experience her last menstrual period. This was the top story in endocrinology last week.
Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease
Adults with thyroid eye disease assigned the human monoclonal antibody teprotumumab were significantly more likely to experience a meaningful improvement in proptosis after 21 weeks of treatment compared with those who received placebo, according to findings from a randomized controlled trial published in The New England Journal of Medicine.
FDA approves teprotumumab for thyroid eye disease
The FDA on Tuesday approved the human monoclonal antibody teprotumumab for the treatment of adults with thyroid eye disease, marking the first drug approved for the condition, according to an agency press release.
Teprotumumab significantly improves proptosis in thyroid eye disease
KOLOA, Hawaii — Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
AACE launches ‘Up to Here’ thyroid awareness campaign
The American Association of Clinical Endocrinologists this week launched the Up To Here campaign to raise awareness of thyroid diseases and to help U.S. residents recognize symptoms, risk factors and the need to seek treatment, according to an association press release.
Stem cell therapy, FDA approvals lead 2019 ophthalmology news
Top thyroid news 2019: treating refractory cancer, thyroid eye disease and more
In 2019, Healio readers were interested in thyroidectomy for Hashimoto’s disease, environmental effects on thyroid function, the limits of thyroid testing, a drug under FDA consideration for thyroid eye disease, subclinical hypothyroidism guidelines, and more.